BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
MWN-AI** Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company dedicated to genetic diseases, announced the presentation of ten moderated digital posters at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, from November 7-10, 2025. These presentations will focus on key findings from the ATTRibute-CM study related to transthyretin amyloid cardiomyopathy (ATTR-CM), particularly highlighting the effects of its investigational drug, acoramidis.
Among the prominent studies presented, Dr. Marianna Fontana from University College London will discuss the implications of acoramidis on all-cause mortality in patients with the p.V142I (V122I) variant of ATTR-CM. Other presentations will explore how acoramidis reduces all-cause mortality and cardiovascular hospitalization through 42 months, regardless of a patient's background or condition status. Notably, Dr. Mathew Maurer from Columbia University will share findings showing that acoramidis significantly lowers NT-proBNP levels, a biomarker associated with heart failure, in a substantial portion of study participants.
Further investigations will address demographic disparities in treatment outcomes, with Dr. Nicole Cyrille-Superville presenting insights on tafamidis, another treatment for ATTR-CM. Geographic differences in the disease's prevalence among U.S. veterans will also be highlighted. The overall focus emphasizes the potential of acoramidis to improve clinical outcomes and quality of life for patients suffering from this debilitating genetic condition.
Attruby™ (acoramidis), indicated for adults with ATTR-CM, aims to mitigate cardiovascular-related mortality and hospitalizations effectively. The safety profile shows mild adverse reactions, predominantly gastrointestinal, with discontinuation rates comparable to placebo.
BridgeBio, founded in 2015, aspires to expedite the development and delivery of innovative therapies for genetic disorders, underpinned by its robust commitment to scientific advancement.
MWN-AI** Analysis
As BridgeBio Pharma (Nasdaq: BBIO) prepares to present pivotal findings from the ATTRibute-CM study at the AHA Scientific Sessions 2025, investor sentiment is expected to rally around the data regarding Acoramidis, particularly its effects on the V142I (V122I) variant population within the ATTR-CM demographic. Given the context of increasing occurrences and healthcare costs associated with transthyretin amyloid cardiomyopathy (ATTR-CM), the market is inclined to focus on BridgeBio’s product as a transformative option for the treatment landscape.
The upcoming digital posters showcase significant outcomes, including reductions in all-cause mortality and cardiovascular-related hospitalizations attributed to Acoramidis. These findings could emphasize the drug's value proposition, potentially leading to expanded adoption in clinical settings. Notably, the study's findings regarding Acoramidis lowering NT-proBNP levels are particularly compelling, as this biomarker is widely recognized for its role in assessing heart failure severity, thus offering tangible clinical benefits for patients.
Investors should closely monitor the reaction from both the medical community and analysts following the presentations. A positive response could catalyze increased stock interest, uplifting BridgeBio’s valuation. Additionally, demographic and geographic insights presented could shed light on market opportunities, allowing BridgeBio to strategize its commercialization efforts more effectively.
Despite strength in the pipeline, potential investors should keep an eye on the adverse reactions reported - such as diarrhea and abdominal pain - as any negative headlines can affect stock performance.
In conclusion, investors are encouraged to consider the potential ramifications of the data presented at the AHA sessions, as it may position BridgeBio as a leader in treating genetic diseases, particularly those linked to cardiomyopathy, thus paving the way for significant market uplift.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the American Heart Association (AHA) Scientific Sessions 2025, taking place in New Orleans, LA from November 7 - 10, 2025.
Moderated Digital Posters:
Acoramidis Effect on All-Cause Mortality in Patients with p.V142I (V122I) Variant ATTR-CM: Findings from the ATTRibute-CM Study
Presenter: Marianna Fontana, M.D., University College London, UK
Date/time: Saturday, November 8 at 3:15 pm CT
Acoramidis Reduces All-Cause Mortality and First Cardiovascular Hospitalization in Patients with Variant Transthyretin Amyloid Cardiomyopathy: Results from the ATTRibute-CM Study
Presenter: Prem Soman, M.D., Ph.D., University of Pittsburgh School of Medicine, U.S.
Date/time: Saturday, November 8 at 9:15 am CT
Acoramidis Reduces All-Cause Mortality and Cardiovascular-Related Hospitalizations Through Month 42 in Transthyretin Amyloid Cardiomyopathy Across All Pre-specified Patient Subgroups
Presenter: Lily Stern, M.D., Cedars-Sinai Heart Institute, U.S.
Date/time: Saturday, November 8 at 3:15 pm CT
Acoramidis Lowers NT-proBNP in a Larger Proportion of ATTRibute-CM Study Participants with Transthyretin Amyloid Cardiomyopathy Compared with Placebo, Independent of Atrial Fibrillation Status
Presenter: Mathew Maurer, M.D., Columbia University Irving Medical Center, U.S.
Date/time: Saturday, November 8 at 9:15 am CT
Demographic Disparities in Tafamidis Treatment and Clinical Outcomes Across the United States
Presenter: Nicole Cyrille-Superville, M.D., Atrium Health Sanger Heart & Vascular Institute Kenilworth, Charlotte, NC, U.S.
Date/time: Saturday, November 8 at 12:15 pm CT
Geographic Disparities in Transthyretin Amyloid Cardiomyopathy Prevalence in United States Veterans
Presenter: Sandesh Dev, M.D., Southern Arizona VA Health Care System, U.S.
Date/time: Saturday, November 8 at 3:15 pm CT
Serum Transthyretin Levels at Day 28 are Associated with Cardiovascular Outcomes: Insights from the ATTRibute-CM Study
Presenter: Nitasha Sarswat, M.D., UChicago Medicine, U.S.
Date/time: Sunday, November 9 at 3:15 pm CT
Acoramidis Improved Clinical Outcomes, Function, Quality of Life and NT-proBNP in Patients with Transthyretin Amyloid Cardiomyopathy Regardless of Atrial Fibrillation Status at Baseline
Presenter: Richard Cheng, M.D., University of Washington, Seattle, WA, U.S.
Date/time: Sunday, November 9 at 3:15 pm CT
Acoramidis Reduces the Risk of All-Cause Mortality and Cardiovascular-Related Hospitalization Compared with Placebo in Participants with Transthyretin Amyloid Cardiomyopathy and Early-Stage Heart Failure Regardless of Atrial Fibrillation History: Insights from ATTRibute-CM
Presenter: Ronald Witteles, M.D., Stanford University School of Medicine, U.S.
Date/time: Saturday, November 8 at 3:15 pm CT
Vutrisiran Healthcare Resource Utilization, Costs, Discontinuation, and Mortality: A Retrospective Database Analysis
Presenter: Nicole Bart, M.D., Ph.D., St Vincent's Hospital Sydney, AU
Date/time: Monday, November 10 at 10:45 am CT
About Attruby™ (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).
About BridgeBio
BridgeBio Pharma (BridgeBio; Nasdaq: BBIO) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn , X , Facebook , Instagram , and YouTube .
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
FAQ**
How does BridgeBio Pharma Inc. (BBIO) plan to leverage the results from the moderated digital posters presented at the AHA Scientific Sessions 2025 to enhance its market position in the competitive biopharmaceutical landscape?
What steps is BridgeBio Pharma Inc. (BBIO) taking to address potential patient safety concerns related to the reported adverse reactions from Attruby™ in its ongoing clinical trials and future product rollouts?
Can BridgeBio Pharma Inc. (BBIO) provide insights on how the demographic disparities observed in Tafamidis treatment and outcomes may influence its strategic initiatives in marketing and product development for ATTR-CM?
Given the promising outcomes presented in the AHA Scientific Sessions, what are the next steps for BridgeBio Pharma Inc. (BBIO) in advancing the commercialization of Attruby™ for the treatment of transthyretin amyloid cardiomyopathy?
**MWN-AI FAQ is based on asking OpenAI questions about BridgeBio Pharma Inc. (NASDAQ: BBIO).
NASDAQ: BBIO
BBIO Trading
1.43% G/L:
$72.50 Last:
491,859 Volume:
$71.54 Open:
